GOODYN-HC
Control group for research on CD8 T cell-mediated diseases
The GOODSYN-HC study aims to recruit healthy volunteers to provide samples that can be used as a comparison group in research on immune-mediated diseases. These samples will help researchers better understand how the immune system differs between healthy individuals and people affected by conditions such as Good’s syndrome. The study focuses in particular on CD8+ T cells, a type of immune cell involved in the body’s defence mechanisms which has been increasingly associated with many diseases. Researchers will analyse immune cells, inflammatory markers, and antibody profiles to identify differences that may help explain how these diseases develop and affect the immune system. By taking part, healthy volunteers will contribute to research that may improve scientific understanding of immune dysfunction and support future advances in diagnosis and treatment.
About the study
Locations
L-1445 Strassen
L-4354 Esch-sur-Alzette
LUXEMBOURG
L-3555 Dudelange
LUXEMBOURG
Contact
Who can participate?
Eligible participants
You may be eligible to participate if you:
- Are a healthy volunteer between 50 and 80 years of age.
- Have previously been exposed to cytomegalovirus (CMV), confirmed by a positive CMV-IgG blood test. This will be assessed during the study screening.
- Are willing and able to provide written informed consent.
Exclusion criteria
You may not be eligible to participate if you:
- Have an active cancer (people with a history of cancer that has been successfully treated may still be eligible).
- Have an autoimmune disease, including psoriasis.
- Have diabetes.
- Experience frequent or unusually severe infections, such as repeated lung, urinary, or gastrointestinal infections.
- Have an ongoing acute infection, such as a chest infection or severe cold, at the time of enrolment.
- Are currently receiving immunoglobulin therapy.
Not sure about eligibility?
The study team will review each case individually to determine eligibility. If you are unsure whether you are eligible, do not hesitate to contact us
What will participants do?
01.
Sign an informed consent form
This must be completed before any study procedures begin.
02.
Provide an initial blood sample
This will be used to determine whether you meet the study’s eligibility criteria, including testing for previous exposure to cytomegalovirus (CMV).
03.
Attend an additional study visit (if selected)
During this visit, you will provide a second blood sample.
Contact & location
Luxembourg Institute of Health – Clinical Investigation Unit
1A-B rue Thomas Edison
L-1445 Strassen
Dedicated clinical investigation unit at LIH for early-phase studies, biobanking and translational research.
Luxembourg Institute of Health (LIH), House of Bio Health (HoBH)
29, rue Henri Koch
L-4354 Esch-sur-Alzette
LUXEMBOURG
Luxembourg Institute of Health (LIH), Integrated BioBank of Luxembourg (IBBL)
1, rue Louis Rech
L-3555 Dudelange
LUXEMBOURG
Study team
Participating institutions
Funded by
Luxembourg National Research Fund (FNR)
The Ministry of Higher Education and Research (MESR)
Related news & updates
Small country, significant capacity
Luxembourg may be one of Europe’s smallest countries, but the Luxembourg Research Clinic demonstrates how its highly connected national network…
Clinnova Consortium Agreement signed, marking a major milestone for health research across Europe
Thanks to a joint investment from LIH and the Ministry of Health, the national biobank accessible to LRC studies has…
Building on Luxembourg’s Research Strengths
The Luxembourg Research Clinic brings together the strengths of Luxembourg’s leading healthcare, research and academic institutions, building on established expertise…
Related events
Clinical Research Luxembourg Conference
Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…